top of page
​BioFinland Member

BioFinland Member

Anison Therapeutics

Anison Therapeutics
Company name

Anison Therapeutics


Talvitie 11, as 2, FI-20610 Turku


+358 50 593 2682





Contact person

Kenneth Sundberg


Kenneth Sundberg

Main categories

Drug Discovery and Development / Drug Delivery, Biomaterials

Last updated

22 February 2023

Company profile

Anison Therapeutics aims at building a portfolio of technologies targeting the Human Papillomavirus(HPV)-mediated diseases.

The first steps are taken by dedicated efforts towards developing and commercializing a topical cream (containing a HPV targeting compound) that addresses unmet medical needs for genital warts, with preclinical studies projected to start during the first half of 2023. Longer term, the company will also focus on the treatment of genital pre-cancerous lesions and other HPV-associated warts, including common and foot(plantar) warts, thus becoming a successful company with solid sales growth and a strong pipeline of new products to be introduced to the roughly >$8Bn market.

bottom of page